Results 21 to 30 of about 27,075 (224)

The PARP-1 inhibitor Olaparib causes retention of γ-H2AX foci in BRCA1 heterozygote cells following exposure to gamma radiation [PDF]

, 2013
This article is made available through the Brunel Open Access Publishing Fund. Copyright © 2013 Emma C. Bourton et al. This is an open access article distributed under the Creative Commons Attribution Li-cense, which permits unrestricted use ...
Bourton, EC, Plowman, PN, Adam Zahir, S, Parris, CN, Harvey, AJ   +4 more
core   +1 more source

Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress

Frontiers in Oncology, 2022
The poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) Olaparib is a widely used targeted therapy for a variety of solid tumors with homologous recombination deficiency (HRD) caused by mutation of BRCA1/2 or other DNA repair genes.
Tao Han, Jing Tong, Jing Tong, Mengxin Wang, Yu Gan, Bo Gao, Jiaxiang Chen, Youxun Liu, Qian Hao, Qian Hao, Xiang Zhou, Xiang Zhou, Xiang Zhou, Xiang Zhou   +13 more
doaj   +1 more source

Defective DNA repair mechanisms in prostate cancer: impact of olaparib [PDF]

, 2017
Francesca De Felice,1 Vincenzo Tombolini,1 Francesco Marampon,2 Angela Musella,3 Claudia Marchetti3 1Department of Radiotherapy, Policlinico Umberto I, “Sapienza” University of Rome, Rome, 2Department of Biotechnological and Applied Clinical
Musella A, Marchetti C., De Felice F, Marampon F, Tombolini V, Marchetti C   +5 more
core   +1 more source

The PARP Inhibitor Olaparib Modulates the Transcriptional Regulatory Networks of Long Non-Coding RNAs during Vasculogenic Mimicry

Cells, 2020
In highly metastatic tumors, vasculogenic mimicry (VM) involves the acquisition by tumor cells of endothelial-like traits. Poly-(ADP-ribose) polymerase (PARP) inhibitors are currently used against tumors displaying BRCA1/2-dependent deficient homologous ...
Mónica Fernández-Cortés, Eduardo Andrés-León, Francisco Javier Oliver   +2 more
doaj   +1 more source

A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer [PDF]

, 2021
Preclinical studies have shown synergistic effects when combining PARP1/2 inhibitors and platinum drugs in BRCA1/2 mutated cancer cell models. After a formulation change of olaparib from capsules to tablets, we initiated a dose finding study of olaparib ...
Marchetti, Serena, Sonke, Gabe S, Linn, Sabine C, Schellens, Jan H M, Huitema, Alwin D R, Schouten, Philip C, Dackus, Gwen M H E, Geenen, Jill J J, Jóźwiak, Katarzyna, Pluim, Dick, Beijnen, Jos H   +10 more
core  

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

OncoImmunology, 2022
PARP inhibitors are synthetically lethal with BRCA1/2 mutations, and in this setting, accumulation of DNA damage leads to cell death. Because increased DNA damage and subsequent immune activation can prime an anti-tumor immune response, we studied the ...
Anna D. Staniszewska, Joshua Armenia, Matthew King, Chrysiis Michaloglou, Avinash Reddy, Maneesh Singh, Maryann San Martin, Laura Prickett, Zena Wilson, Theresa Proia, Deanna Russell, Morgan Thomas, Oona Delpuech, Mark J. O’Connor, Elisabetta Leo, Helen Angell, Viia Valge-Archer   +16 more
doaj   +1 more source

An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study

, 2020
Objective: Olaparib is a potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1, 2, and 3 with potential activity in endometrial cancer (EC). Methods: In this window-of-opportunity trial, women with operable type 1 EC received olaparib oral tablets ...
Romero, Ignacio, Poveda, Andrés, Coronado Martín, Pluvio Jesús   +2 more
core   +1 more source

Olaparib for Metastatic Castration-Resistant Prostate Cancer [PDF]

, 2020
Contains fulltext : 220820.pdf (Publisher’s version ) (Open Access)BACKGROUND: Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to ...
Kohlmann, A., Shore, Neal, Kohlmann, A, Shore, N, Mateo, J, Fizazi, K, Sandhu, S., Fizazi, K., Sandhu, S, Kang, Jinyu, Saad, F, Olmos, David, Twardowski, P., Sartor, Oliver, Mehra, N., Hussain, M., Mateo, Joaquin, Burgents, Joseph, Sartor, O, Olmos, D., Sandhu, Shahneen, Fizazi, Karim, Kohlmann, Alexander, Saad, Fred, de Bono, Johann, Adelman, Carrie A, Adelman, CA, Goessl, Carsten, Olmos, D, Thiery-Vuillemin, Antoine, Thiery-Vuillemin, A, Burgents, J, Thiery-Vuillemin, A., Twardowski, P, Hussain, Maha, Chi, Kim N, Mehra, Niven, Mateo, J., Burgents, J., Shore, N., Chi, KN, Agarwal, N, Wu, W., de Bono, J, Goessl, C, Chi, K.N., Wu, W, Sartor, O., Goessl, C., Adelman, Caroline, Mehra, N, Hussain, M, Agarwal, Neeraj, Twardowski, Przemyslaw, Kang, J., Kang, J, de-Bono, Johann, Wu, Wenting, Saad, F., Bono, J. de, Agarwal, N.   +60 more
core   +1 more source

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model [PDF]

, 2017
Clinical trials are studying the benefits of combining the PARP-1 inhibitor olaparib with chemotherapy and radiotherapy treatment in a variety of cancer increasing the therapeutic ratio for olaparib may come from its ability to modify the tumour ...
Mark J. O’Connor, Zafarana, Gaetano, Marcel Verheij, Rottenberg, Sven, Borst, Gerben R; id_orcid, McKee, Trevor, Bristow, Robert G; id_orcid, Ramya Kumareswaran, Seyda Telli, Bristow, Robert G, Yücel, Hatice, Trevor McKee, Borst, Gerben R, O'Connor, Mark J, Gerben R. Borst, Jos Jonkers, Kumareswaran, Ramya, Robert G. Bristow, Hatice Yücel, Trevor Do, Do, Trevor, Sven Rottenberg, Telli, Seyda, Jonkers, Jos, Verheij, Marcel, Gaetano Zafarana   +25 more
core   +2 more sources

Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature

BMC Pulmonary Medicine, 2023
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has demonstrated effectiveness in treating ovarian, breast, and other cancers, particularly those with specific molecular subtypes including, but not limited to, BRCA1/2 mutations ...
Hiroshi Ishimoto, Noriho Sakamoto, Takashi Kido, Mutsumi Ozasa, Shin Tsutsui, Mayako Mori, Daichi Setoguchi, Shinnosuke Takemoto, Yasushi Obase, Yuji Ishimatsu, Chiharu Tomonaga, Kanako Matsumoto, Sachiko Morisaki, Kiyonori Miura, Hiroshi Mukae   +14 more
doaj   +1 more source